Subcutaneous Immune Globulin (SCIG)
Some patients with primary immune deficiency are injected with intravenous immune globulin (IVIG) every 3-4 weeks. Now a subcutaneous immune globulin (SCIG) has also been approved in the US for this indication (Vivaglobin - CSL Behring). SCIG has been used in Europe for about 10 years....
Cannot Access - We are sorry, but you cannot access the requested article.
If you have already purchased this article, or have a subscription to The Medical Letter on Drugs and Therapeutics, please login or register to view it online.
If you have already purchased this article, or have a subscription to The Medical Letter on Drugs and Therapeutics, please login or register to view it online.
Information about the article:
Title: Subcutaneous Immune Globulin (SCIG)
Publication: The Medical Letter on Drugs and Therapeutics
Issue #: 1258
Article Code: 1258b
Date: April 9, 2007
Volume: 49
Pages: 31-32
Publication: The Medical Letter on Drugs and Therapeutics
Issue #: 1258
Article Code: 1258b
Date: April 9, 2007
Volume: 49
Pages: 31-32
Subscribe to The Medical Letter on Drugs and Therapeutics for instant access to this article. Add this downloadable, electronic article to your cart (U.S. English version only)
